儿童肿瘤早期临床试验入排标准复杂且缺乏依据:ITCC联盟分析与标准化建议
器官功能阈值与洗脱期高度异质,69%试验在入选和排除部分重复类似标准,高频且相关标准中位仅7%在方案内有科学依据。作者建议实施循证且医学相关的标准以优化入组。
要点
- 儿童早期试验入排标准数量中位28条,近年显著增加。
- 器官功能阈值和洗脱期高度异质,69%试验重复标准。
- 仅7%高频相关标准有方案内科学依据,需标准化。
核心结论
- 儿童肿瘤早期试验入排标准日益复杂、异质且大多缺乏依据,建议实施循证且医学相关的标准以优化入组与代表性。
主要发现
- 每方案中位28条标准(范围12-49),2011—2016与2017—2020年间显著增加(p=0.05)。
- 器官功能阈值和洗脱期存在显著异质性,与试验药物特征无关。
- 69%的试验在入选和排除部分重复类似标准。
- 高频且相关标准中位仅7%(范围0%-62%)在方案内有科学依据,部分排除类别完全无依据。
关键数值与推荐
- 高频标准定义为出现在>66%方案中,平均频率为33%-66%,低频为<33%。
临床怎么用
- 建议采用循证且医学相关的入排要求,减少不必要的重复和异质性,以优化患者入组和代表性。
- 协调标准以在维持安全性的同时确保更广泛地获得创新疗法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Eligibility criteria safeguard trial integrity and safety, yet restrictive requirements frequently limit patient access and generalizability. While initiatives exist to simplify criteria in adult populations, evidence supporting their use and justification within pediatric oncology remains undefined. METHODS: Sixty-four protocols from 48 ITCC phase I-II trials (2011-2020) were evaluated. Protocol, literature analysis, and regulatory standards review was performed. Eligibility criteria were quantified and categorized by frequency: High (appeared in >66% of protocols), average (33%-66%), and low (<33%). For each high-frequency and relevant criteria identified in the literature review, the scientific justification provided within the trial protocol was assessed. RESULTS: Analysis revealed a median of 28 criteria per protocol (range 12-49), with a significant increase between 2011-2016 and 2017-2020 (p = 0.05). Substantial heterogeneity was observed in organ function thresholds and washout periods, irrespective of investigational agent characteristics. Repetition was prevalent; 69% of trials repeated similar criteria in both inclusion and exclusion sections. Notably, a median of only 7% (range 0%-62%) of high-frequency and relevant criteria possessed scientific justification within the protocol, with several exclusion categories lacking justification entirely. CONCLUSION: Pediatric early-phase trial eligibility criteria are increasingly complex, heterogeneous and predominantly lacking justification. We recommend implementing evidence-based, medically relevant requirements to optimize patient accrual and representation. Harmonizing these standards is essential to maintain safety while ensuring broader access to innovative therapies in pediatric drug development.
引用
- Ilan U, Rubio-San-Simón A, van Eijkelenburg N, et al. Eligibility criteria in pediatric oncology phase I and II clinical trials: Analysis and recommendations for standardization from the Innovative Therapies for Children and Adolescents with Cancer (ITCC) Consortium. Eur J Cancer. 2026. PMID: 42202478. doi:10.1016/j.ejca.2026.116830
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。